Medifocus receives two patents to expand IP portfolio

Oct 19 2010

Medifocus, Inc. (OTC:MDFZF.PK and TSXV:MFS) is pleased to announce that it has recently received notice of allowances for two additional international patents to expand its extensive Intellectual Properties (IP) portfolio in addition to the patents Medifocus has exclusively licensed from the Massachusetts Institute of Technology (MIT). The core MIT patents allows the Company to develop tumor-targeted focused heat treatment systems using the adaptive phased array (APA) radar technique which was developed at MIT by Dr. Alan J. Fenn as part of the Strategic Defense Initiative.

“Monopole Phased Array Thermotherapy for Deep Tumor Therapy”

The first of the recently allowed patents is "Thermotherapy Method for Treatment and Prevention of Cancer and Breast Cancer in Male and Female Patients" in Japan. This patent has already been granted by the United States Patent and Trademark Office (USPTO). This patent and several other Company patents forms the basis of the Company's Clinical Breast Cancer Treatment System, which has already been developed and has been approved by both the United States Food and Drug Administration (FDA), and Health Canada to allow Medifocus to initiate its Phase III Pivotal Clinical Trial both in the USA and Canada. Successful completion of the Phase III trial will lead to commercial approval of the product.

The second recently allowed patent is: "Monopole Phased Array Thermotherapy for Deep Tumor Therapy" which was allowed by the European Patent Office (EPO) and which has already been granted by the USPTO. This patent will allow the company to develop additional focused heat treatment systems for Deep Seated Tumors for Lung, Liver, Ovarian, Prostate, and other tumors.

The allowances of these two patents are significant additions to Medifocus' extensive IP portfolio to commercially expand on a global basis.